KR102119316B1 - Cosmetic composition containing Paeonia suffruticosa complex extract - Google Patents
Cosmetic composition containing Paeonia suffruticosa complex extract Download PDFInfo
- Publication number
- KR102119316B1 KR102119316B1 KR1020180115133A KR20180115133A KR102119316B1 KR 102119316 B1 KR102119316 B1 KR 102119316B1 KR 1020180115133 A KR1020180115133 A KR 1020180115133A KR 20180115133 A KR20180115133 A KR 20180115133A KR 102119316 B1 KR102119316 B1 KR 102119316B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- peony
- cosmetic composition
- complex extract
- motherwort
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000002537 cosmetic Substances 0.000 title claims abstract description 28
- 240000005001 Paeonia suffruticosa Species 0.000 title description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 title description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 57
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 26
- 241000207925 Leonurus Species 0.000 claims abstract description 26
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 26
- 235000011511 Diospyros Nutrition 0.000 claims abstract description 17
- 230000002087 whitening effect Effects 0.000 claims abstract description 14
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 3
- 244000236655 Diospyros kaki Species 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 8
- 230000037303 wrinkles Effects 0.000 claims description 8
- 241000234435 Lilium Species 0.000 claims description 6
- 239000011049 pearl Substances 0.000 abstract description 22
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 241000723267 Diospyros Species 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 5
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 241000736199 Paeonia Species 0.000 description 54
- 238000002360 preparation method Methods 0.000 description 52
- 230000000052 comparative effect Effects 0.000 description 20
- 230000003078 antioxidant effect Effects 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000004209 hair Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 241000208838 Asteraceae Species 0.000 description 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241001474374 Blennius Species 0.000 description 4
- 241001164374 Calyx Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229940027779 persimmon extract Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- -1 skins Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241001485474 Adonis amurensis Species 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241001512722 Ecklonia cava Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 241000784222 Inula japonica Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 240000003271 Leonurus japonicus Species 0.000 description 1
- 241000533950 Leucojum Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000195473 Sargassum fulvellum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초의 복합추출물을 함유하는 화장료 조성물에 관한 것으로, 상기 유효성분으로서의 복합추출물은 천연 추출물로 이루어져 부작용과 피부 자극성이 적으며 우수한 항산, 항염, 주름개선 및 미백 효과를 나타낸다.The present invention relates to a cosmetic composition containing a complex extract of peony flowers, sseonhwa, pearls, persimmons, motherwort, sunbokhwa, yulmu and motherwort, and the complex extract as an active ingredient is made of natural extracts and has little side effects and irritation to skin. Excellent anti-acid, anti-inflammatory, anti-wrinkle and whitening effect.
Description
본 발명은 모란 복합추출물을 함유하는 화장료 조성물에 관한 것으로, 구체적으로는 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초의 복합추출물을 유효성분으로 함유하여, 항산화, 항염, 주름개선 및 미백활성이 우수한 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing a complex peony extract, specifically, contains a complex extract of peony flowers, ssoonhwa, pearls, persimmons, caps, sunbokhwa, yulmu and motherwort as an active ingredient, antioxidant, anti-inflammatory, wrinkles It relates to a cosmetic composition excellent in improving and whitening activity.
최근 천연물 유래의 화장품에 관한 관심이 점점 커지고 있다. 또한 기능성 화장품에 대한 요구가 증가하면서 기능성 성분으로 사용되는 각종 화학성분들로 인하여 오히려 피부의 보호능력이나 재생능력이 저하되는 문제가 발생하고 있다. 이에 따라 스킨, 로션을 비롯해 색조 화장품에 이르기까지 천연물 소재의 화장품을 직접 만들어 사용하는 것이 유행하고 있기도 하다. 아토피 등의 피부질환을 가지고 있거나, 민감성 피부를 가진 사람들의 경우에는 피부 자극을 최소화하면서 피부 개선활성이 우수한 천연물 유래의 화장품에 대한 관심이 더욱 높아지고 있다.Recently, interest in cosmetics derived from natural products is growing. In addition, as the demand for functional cosmetics increases, there is a problem in that the protective or regenerating ability of the skin is deteriorated due to various chemical components used as functional ingredients. Accordingly, it is popular to make and use cosmetics made from natural materials, including skins, lotions, and color cosmetics. In the case of people with skin diseases such as atopy or sensitive skin, interest in cosmetics derived from natural products having excellent skin improvement activity while minimizing skin irritation is increasing.
모란(Paeonia suffruticosa)은 미나리아재비과에 속하는 낙엽관목이다. 목단(牧丹)이라고도 하며, 높이는 2m 정도 자라며 가지가 굵고 털이 없다. 잎은 어긋나고 2회 우상복엽이며, 소엽은 다시 두세 개로 갈라지기도 하고 표면에는 털이 없다. 꽃은 5월에 피고 양성이며 지름은 15㎝ 이상이고, 홍자색이지만 백색, 홍색, 담홍색, 주홍색, 농홍색, 자색 및 황색이 있다. 꽃잎은 5∼7개인데 많은 꽃잎이 달리는 품종이 개발되어 있다. 꽃이 피는 기간은 2∼3일이지만 꽃잎이 많은 종류는 7∼10일간 피기도 한다. 뿌리의 껍질은 해열, 진통, 진경(鎭痙), 구어혈(驅瘀血), 통경(通經), 양혈(凉血), 소염(消炎)의 효능이 있어 약재로 이용한다. 약성은 양(凉)하고 신고(辛苦)하다. 각종 열성병의 항진기(亢進期), 골증노열(骨蒸勞熱), 경간이나 각종 혈행장애, 월경불순, 폐경, 질타손상(跌打損傷), 옹종(癰腫) 등에 탕(湯), 환(丸) 또는 산제(散劑)로 하여 복용한다.Peony (Paeonia suffruticosa) is a deciduous tree belonging to the family Asteraceae. Also called Mokdan, it grows about 2m in height and has thick, hairless branches. Leaves are alternate, 2 times upper right biplane, and lobule is divided into two or three again, and there is no hair on the surface. Flowers bloom in May, are benign, have a diameter of 15 cm or more, and are reddish purple, but are white, red, pink, scarlet, deep red, purple, and yellow. There are 5 to 7 petals, but varieties with many petals running have been developed. The flowering period is 2 to 3 days, but many petals bloom 7 to 10 days. The bark of the root has the efficacy of antipyretic, analgesic, jinkyung (鎭痙), gueohyeol (驅瘀血), tongyeong (通經), yanghyeol (凉血), anti-inflammatory (消炎) and is used as a medicine. Yakseong is positive and declaring. Hyperthermia of various febrile diseases, sensitizing fever, span and various blood circulation disorders, menstrual disorders, menopause, vaginal damage, ongjong, etc. Take it as a pill or powder.
종래 모란의 뿌리껍질로 만든 약재인 목단피(牧丹皮)나 모란꽃은 그 피부개선활성으로 인해, 항산화, 주름개선, 항염, 미백용 화장품 등의 원료로 널리 사용되어 왔다.Traditionally, peony flower or peony flower, which is a medicine made from the root skin of peonies, has been widely used as a raw material for anti-oxidation, anti-wrinkle, anti-inflammatory, and whitening cosmetics due to its skin improvement activity.
대한민국 공개특허 제2011-0001538호 "항산화 및 미백 활성을 갖는 꽃 혼합 추출물 및 그 추출방법 및 그 꽃 혼합 추출물을 함유하는 화장료 조성물"에는 '모란꽃을 포함하는 꽃 혼합추출물이 항산화 및 미백활성을 가진다'는 것이 개시되어 있으며, 대한민국 등록특허 제1485104호 "한약재 추출물을 함유하는 화장료 조성물"에는 '목단피 추출물이 우수한 항산화 및 항염증 효과를 가진다'는 것이 개시되어 있다.Republic of Korea Patent Publication No. 2011-0001538 "flower mixed extract having antioxidant and whitening activity and a method for extracting it and a cosmetic composition containing the flower mixed extract" "flower mixed extract containing peony flower has antioxidant and whitening activity" In the Republic of Korea Patent Registration No. 1485104, "Cosmetic composition containing herbal extracts," it is disclosed that the'mokdanpi extract has excellent antioxidant and anti-inflammatory effects'.
본 발명자들은 피부개선활성을 가지는 다양한 천연물들에 대하여 연구하였으며, 모란꽃을 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초와의 복합추출물로 이용하는 경우 더욱 우수한 항산화, 항염, 주름개선 및 미백활성을 가진다는 것을 확인하여 본 발명을 완성하였다.The present inventors have researched various natural products having skin improvement activity, and when using peony flower as a complex extract with snail, pearl, persimmon, cap, pear, yulmu and motherwort, more excellent antioxidant, anti-inflammatory, wrinkle improvement and whitening The present invention was completed by confirming that it has activity.
본 발명은 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초의 복합추출물을 유효성분으로 함유하여 우수한 항산화, 항염, 주름개선 및 미백활성을 나타내는 화장료 조성물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a cosmetic composition exhibiting excellent antioxidant, anti-inflammatory, anti-wrinkle and whitening activity by containing a complex extract of peony flowers, sseonhwa, pearls, persimmons, motherwort, sunbokhwa, yulmu and motherwort .
상기 목적을 달성하기 위하여 본 발명에 따르면, 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초의 복합추출물을 함유하는 화장료 조성물이 제공된다.According to the present invention to achieve the above object, there is provided a cosmetic composition containing a complex extract of peony flowers, sseonhwa, pearls, persimmons, caps, sunbokhwa, yulmu and motherwort.
상기 복합추출물은 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초를 혼합한 후, 열수 추출하거나, 물, 탄소수 1~4의 저급 알코올, 에틸아세테이트, 글리세린, 에틸렌글리콜, 프로필렌글리콜 및 부틸렌글리콜로 이루어진 군으로부터 선택된 적어도 하나의 용매로 추출하여 제조되는 것이다.The complex extract is a peony flower, sseonhwa, pearl, persimmon, hat half, sunbok, yulmu and motherwort, then hot water extracted or water, lower alcohol having 1 to 4 carbon atoms, ethyl acetate, glycerin, ethylene glycol, propylene glycol And it is prepared by extraction with at least one solvent selected from the group consisting of butylene glycol.
상기 복합추출물은 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초를 각각 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2의 중량비율로 혼합한 후 추출된 것이다.The complex extract is peony flower, sseonhwa, pearls, persimmon, hat half, sunbokhwa, Yulmu and motherwort, respectively 1~2: 1~2: 1~2: 1~2: 1~2: 1~2 : It is extracted after mixing at a weight ratio of 1 to 2.
상기 복합추출물은 화장료 조성물 전체 중량에 대하여 0.01~10 중량% 포함된다.The composite extract is contained in an amount of 0.01 to 10% by weight based on the total weight of the cosmetic composition.
상기 화장료 조성물은 항산화용, 항염용, 주름개선용 또는 미백용으로 사용될 수 있다.The cosmetic composition may be used for antioxidant, anti-inflammatory, wrinkle improvement or whitening.
본 발명에 따른 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초 복합추출물은 천연 추출물로 이루어져 부작용과 피부 자극이 적으며 우수한 항산화, 항염, 주름개선 및 미백활성을 나타내므로 화장료로 유용하게 사용될 수 있다.The peony flower, perennial, pearl, persimmon, motherwort, sunbokhwa, yulmu and motherwort complex extracts made of natural extracts have less side effects and less skin irritation and exhibit excellent antioxidant, anti-inflammatory, anti-wrinkle and whitening activity. It can be useful.
도 1은 본 발명의 일 실시예에 따른 복합추출물의 Cell viability를 나타내는 그래프이다.
도 2는 본 발명의 일 실시예에 따른 복합추출물의 NO assay 결과를 나타내는 그래프이다.
도 3은 본 발명의 일 실시예에 따른 복합추출물의 MMP-1 assay 결과를 나타내는 그래프이다.
도 4는 본 발명의 일 실시예에 따른 복합추출물의 Procollagen assay 결과를 나타내는 그래프이다.
도 5는 본 발명의 일 실시예에 따른 복합추출물의 Melanogenesis 저해효과를 나타내는 그래프이다.1 is a graph showing the cell viability of a composite extract according to an embodiment of the present invention.
Figure 2 is a graph showing the NO assay results of the complex extract according to an embodiment of the present invention.
3 is a graph showing the results of the MMP-1 assay of the complex extract according to an embodiment of the present invention.
4 is a graph showing the results of a Procollagen assay of a complex extract according to an embodiment of the present invention.
5 is a graph showing the effect of inhibiting the melanan complex extract according to an embodiment of the present invention.
이하 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 모란꽃을 포함하는 8가지의 천연물의 복합추출물을 유효성분으로 함유하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing a complex extract of eight natural products including peony flowers as an active ingredient.
본 발명의 복합추출물을 구성하는 원료 중 하나인 설련화(Adonis amurensis)는 쌍떡잎식물 이판화군 미나리아재비목 미나리아재비과의 여러해살이풀이다. 원일초, 복수초라고도 한다. 산지 숲 속 그늘에서 자란다. 높이 10∼30cm이다. 뿌리줄기가 짧고 굵으며 흑갈색의 잔뿌리가 많이 나온다. 줄기는 윗부분에서 갈라지며 털이 없거나 밑부분의 잎은 막질로서 원줄기를 둘러싼다. 잎은 양면에 털이 없거나 뒷면에 작은 털이 있으며, 밑에서는 잎몸이 없고 밑부분뿐이며 위로 올라가면서 어긋나고 깃꼴로 두 번 잘게 갈라진다. 꽃은 4월 초순에 피고 노란색이며 지름 3∼4cm로 원줄기와 가지 끝에 1개씩 달린다. 꽃받침조각은 짙은 녹색으로 여러 개이고 꽃잎은 20∼30개가 수평으로 퍼지며 수술은 많고 꽃밥은 길이 1∼2mm이다. 열매는 수과로 길이 1cm 정도의 꽃턱에 모여 달리며, 공 모양으로 가는 털이 있다. 한방과 민간에서 진통제, 창종, 강심제(强心劑), 이뇨제(利尿劑)로 사용한다. 본 발명에서는 설련화의 전초 또는 꽃을 사용한다.One of the raw materials constituting the complex extract of the present invention, Adonis amurensis, is a perennial plant of the family Asteraceae, Asteraceae, Asteraceae. It is also referred to as Wonilcho and Vengeance. It grows in the shade in a mountainous forest. It is 10-30cm in height. The rootstock is short, thick, and has many dark brown roots. The stem splits from the upper part, and there is no hair or the lower leaf is membranous and surrounds the main stem. The leaves have no hairs on both sides or small hairs on the back, and there are no leaf bodies at the bottom, only the bottom, and they are shifted upward and split into fine feathers. Flowers bloom in early April, yellow, 3-4cm in diameter, hanging one at the end of the main stem and branch. The calyx pieces are dark green, several petals are spread horizontally, 20-30 petals, there are many stamens, and the anther is 1-2mm long. The fruit is a fruit tree and runs on a flower jaw about 1 cm long and has hairs that go into a ball shape. It is used as an analgesic, changjong, gangsimje (强心劑), and a diuretic in oriental medicine and the private sector. In the present invention, the outpost or flower of ssoonhwa is used.
진주(Pearl)는 연체동물 부족류 조개의 체내에 생긴 탄산칼슘을 주성분으로 하는 구슬 모양 또는 반구상의 광택이 나는 이상분비물을 말한다. 진주는 해독, 진정작용과 피부병, 중풍, 손발경련 등에도 효과가 있어 건강보조식품이나 피부미용재료로 폭넓게 사용되고 있다. 특히 진주가루는 성인에게 유용한 칼슘 공급원으로 나노화한 진주가루를 섭취하면 체내로 빠르게 흡수되어 이용되고, 피부에 사용하였을 때 노화를 억제하고 피부를 약산성으로 유지하여 피부 면역력을 증가시켜준다고 알려져 있다.Pearl refers to a bead-like or hemispherical shiny glandular secretion composed mainly of calcium carbonate formed in the body of mollusk tribe shellfish. Pearl is widely used as a dietary supplement or as a beauty ingredient for skin because it is effective in detoxification, sedative action, and skin diseases, paralysis, and cramping. In particular, pearl powder is a calcium source useful for adults, and it is known that ingestion of pearlized nanoparticles is rapidly absorbed into the body and used, and when used on the skin, it suppresses aging and maintains the skin weakly acid to increase skin immunity.
감태(Ecklonia cava)는 갈조식물 다시마목 미역과의 여러해살이 해조이다. 점심대(漸深帶)의 깊은 곳에서 자란다. 줄기는 원기둥 모양이고 밑동은 뿌리 모양이다. 가운뎃부분은 굵고 어릴 때는 속이 차 있으나 다 자란 뒤에는 속이 비기도 한다. 해조류를 구성하는 중요한 조류식물이며 주로 전복과 소라 등의 먹이가 된다. 알긴산이나 요오드, 칼륨을 만드는 주요 원료가 되고, 채취하여 식용으로 이용되기도 한다. Ecklonia cava is a perennial seaweed with brown seaweed kelp tree seaweed. It grows deep in the lunch table. The stem is cylindrical and the base is root-shaped. The middle part is thick and full of the stomach when you are young, but the stomach is empty after it has grown. It is an important algae plant that makes up seaweed and mainly feeds abalone and conch. It is the main raw material for making alginic acid, iodine, and potassium, and is also used for edible purposes.
모자반(Sargassum fulvellum)은 갈조식물 모자반목 모자반과의 바닷말이다. 조간대 하부에서 자란다. 흔히 모자반과에 속하는 대형 갈조류를 통칭하는 말로도 쓰인다. 몸은 외견상 뿌리, 줄기, 잎의 구분이 뚜렷하고, 뿌리는 가반상(假盤狀)이며 1개의 중심 가지를 내어 1∼3m 이상 크게 자란다. 줄기는 세모진 기둥 모양 또는 삼각형이고 비틀린다. 잎은 줄기에서 기부 쪽으로 향하여 나며 휘어지고, 주걱 모양 또는 타원형을 하고 잎 중앙부까지 중륵(中肋)이 생긴다. 상부의 잎은 바소 모양이고 가장자리에 톱니 모양의 돌기가 나며, 온몸에는 줄기로부터 기포(氣胞)가 생긴다. 모자반속의 많은 종류가 식용되기도 하며, 알긴산 등 해조 공업의 원료로 이용되거나 비료로도 쓰인다. Sargassum fulvellum is the seahorse of the brown algae capsicum cap. It grows under the intertidal zone. It is also commonly used as a term for a large brown algae belonging to the mother-family. The body is apparently distinct from the roots, stems, and leaves, and the roots are gaban-shaped and grow out larger than 1~3m by cutting out one central branch. The stem is triangular columnar or triangular and twisted. The leaves are curved toward the base from the stem, curved, and have a spatula shape or oval shape, and the middle part of the leaf is formed. The upper leaves are lanceolate and have serrated projections on the edges, and air bubbles are formed from the stems all over the body. Many types of caps are also edible, and are used as raw materials in the seaweed industry such as alginic acid or as fertilizer.
선복화(旋覆花)는 국화과의 금불초(Inula britannica var. japonica(Thunb.) Franch. & Sav)의 꽃을 말린 약재이다. 약리작용으로 기관지의 항경련작용, 이뇨작용 등이 보고되었다. 생김새는 편구형 또는 구형이며 여러 개의 총포로 이루어져 기와 모양으로 배열되어 있다. 포의 조각은 작은 비늘 모양으로 회황색이다. 총포의 밑부분에는 꽃받침의 흔적이 있고 포의 조각과 꽃받침의 바깥 면은 백색 털로 덮여 있다. 씨방의 끝부분에는 백색 털이 많고 그 길이는 약 5mm이다. 여기에 타원형의 작은 씨가 있다.Seonbokhwa (旋覆花) is a medicinal herb that dried the flowers of the Asteraceae (Inula britannica var. japonica (Thunb.) Franch. & Sav). As a pharmacological action, anticonvulsant action and diuretic action of the bronchus were reported. Appearance is either spheroidal or spherical and consists of several guns arranged in a tile shape. The pieces of the gun are small, scaly and grayish-yellow. At the bottom of the gun, there are traces of calyx, and the fragments of the gun and the outer surface of the calyx are covered with white fur. There are many white hairs at the end of ovary and the length is about 5mm. Here is a small oval seed.
율무(Coix lachrymajobi var. mayuen)는 외떡잎식물 벼목 화본과의 한해살이풀이다. 1∼1.5m까지 자라며, 속이 딱딱하며 곧게 자라고 가지가 갈라진다. 잎은 어긋나고 바소꼴이며 나비 약 2.5cm로서 밑부분은 잎집으로 된다. 꽃은 7∼9월에 피고 잎겨드랑이에서 나온 꽃이삭 끝에 길이 3cm 정도의 수꽃이삭이 달린다. 밑부분에 타원형의 잎집에 싸여 있는 암꽃이삭이 있다. 포는 딱딱하고 타원 모양이며 길이 약 1.2cm로서 검은빛을 띤 갈색으로 익는다. 씨방이 성숙하면 잎집은 딱딱해지고 검은 갈색으로 된다. 열매는 견과로서 10월에 익는다. 번식은 종자로 한다. 중국 원산의 귀화식물로서 약료작물로 재배한다. 종자를 의이인(薏苡仁)이라고 하는데, 차 등으로 먹거나 이뇨, 진통, 진경, 강장작용이 있으므로 부종, 신경통, 류머티즘, 방광결석 등에 약재로 쓴다. 생잎은 차 대용으로 쓰고 뿌리를 황달과 신경통에 쓴다. 줄기에 달린 잎은 사료로도 쓴다. 본 발명에서는 율무의 열매를 사용한다.Yulmu (Coix lachrymajobi var. mayuen) is an annual plant of the monocotyledonous plant. It grows to 1~1.5m, has a hard inside, and grows straight and branches are split. The leaves are alternate, lanceolate, and the butterfly is about 2.5cm, and the lower part becomes the leaf sheath. Flowers bloom in July-September, and 3cm long male hairs hang at the end of the flower ear from the leaf axil. There is a female ear wrapped in an oval leaf house at the bottom. The fore is hard, elliptical, about 1.2 cm long, and ripens into a blackish brown. When the ovary matures, the leaf sheath becomes hard and becomes dark brown. Fruits are nuts and ripen in October. Breeding is done with seeds. It is a naturalized plant native to China and cultivated as a medicinal crop. The seeds are called Ui-in (인仁), so they are eaten with tea or used as medicines for edema, neuralgia, rheumatism, and bladder stones because they have diuretic, analgesic, analgesic, and tonic effects. Raw leaves are used as tea substitutes, and roots are used for jaundice and neuralgia. Leaves on the stem are also used as feed. In the present invention, the fruit of Yulmu is used.
익모초(Leonurus japonicus Houtt.)는 쌍떡잎식물 통화식물목 꿀풀과의 두해살이풀이다. 들에서 자라며 높이 약 1m이다. 가지가 갈라지고 줄기 단면은 둔한 사각형이며 흰 털이 나서 흰빛을 띤 녹색으로 보인다. 잎은 마주나는데, 뿌리에 달린 잎은 달걀 모양 원형이며 둔하게 패어 들어간 흔적이 있고, 줄기에 달린 잎은 3개로 갈라진다. 갈래조각은 깃꼴로서 다시 2∼3개로 갈라지고 톱니가 있다. 꽃은 7∼8월에 연한 붉은 자주색으로 피는데, 길이 6∼7mm이며 마디에 층층으로 달린다. 매는 작은 견과로서 넓은 달걀 모양이고 9∼10월에 익으며 꽃받침 속에 들어 있다. 종자는 3개의 능선이 있고 길이 2∼2.5mm이다. 포기 전체를 말려서 산후의 지혈과 복통에 사용한다. 본 발명에서는 익모초의 전초, 줄기 또는 잎을 사용한다.The motherwort (Leonurus japonicus Houtt.) is a biennial plant of the dicotyledonous plant, the honeydew. It grows in the field and is about 1m high. The branches are split, the stem cross section is dull square, and white hairs appear white and green. The leaves face each other, and the leaves attached to the roots are egg-shaped, circular, and there are dull marks, and the leaves attached to the stem are divided into three. The forked pieces are feathers, divided into 2-3 pieces again, and have serrated teeth. Flowers bloom light red-purple in July-August, 6-7mm long, and run in layers at nodes. The hawk is a small nut and has a wide egg shape and ripens in September to October and is in the calyx. Seeds have 3 ridges and are 2~2.5mm long. Dry the entire bag and use it for postpartum hemostasis and abdominal pain. In the present invention, the outpost, stem or leaf of motherwort is used.
본 발명의 일 구체예에 따르면, 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초 복합추출물은 다음과 같은 방법에 의하여 제조된다. 먼저, 세척 건조된 모란꽃, 설련화, 진주분말, 감태, 모자반, 선복화, 율무 및 익모초를 혼합하여 혼합물을 제조한다. 이어서, 이 혼합물을 열수추출하거나, 물, 탄소수 1~4의 저급 알코올, 에틸아세테이트, 글리세린, 에틸렌글리콜, 프로필렌글리콜 및 부틸렌글리콜로 이루어진 군으로부터 선택된 적어도 하나의 용매로 추출하여 추출물을 제조한다. 추출은 통상의 방법에 따라 이루어질 수 있다.According to one embodiment of the present invention, the peony flower, sseonhwa, pearls, persimmons, caps, sunbokhwa, yulmu and motherwort complex extracts are prepared by the following method. First, a mixture is prepared by mixing washed and dried peony flowers, sseonhwa, pearl powder, persimmon, cap, bokbok, yulmu and motherwort. Subsequently, the mixture is extracted with hot water or extracted with at least one solvent selected from the group consisting of water, lower alcohol having 1 to 4 carbon atoms, ethyl acetate, glycerin, ethylene glycol, propylene glycol, and butylene glycol. Extraction can be performed according to a conventional method.
바람직하게는 상기 복합추출물은 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초를 각각 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2의 중량비율로 혼합한 후 추출되거나, 각각의 추출물을 제조한 후 각각을 상기 비율로 혼합하여 이루어질 수 있다. 가장 바람직하게는 1 : 1 : 2 : 1 : 2 : 1 : 1 : 2의 중량비율로 혼합되어 이루어진다.Preferably, the complex extract is peony flower, sseonhwa, pearls, persimmons, caps, bokbok, yulmu, and motherwort, respectively 1~2: 1~2: 1~2: 1~2: 1~2: 1~2: 1~2: It may be extracted after mixing at a weight ratio of 1~2, or after preparing each extract and mixing each at the above ratio. Most preferably, it is made by mixing at a weight ratio of 1:1:2:1:2:1:1:1.
상기 복합추출물은 화장료 조성물 전체 중량에 대하여 0.01~10 중량% 포함된다.The composite extract is contained in an amount of 0.01 to 10% by weight based on the total weight of the cosmetic composition.
유효성분으로서의 상기 모란꽃, 설련화, 진주, 감태, 모자반, 선복화, 율무 및 익모초 복합추출물은 모란꽃 추출물만을 사용하는 경우와 비교해 볼 때, 그 상승작용에 의하여 더욱 우수한 항산화효과, 항염증효과, 주름개선효과 및 미백효과를 나타냄을 확인하였다. 그러므로 이를 유효성분으로 함유하는 화장료 조성물은 항산화용, 항염용, 주름개선용 또는 미백용 화장품으로 사용될 수 있다.Compared to the case where only the peony flower extract is used as the active ingredient, the peony flower, snow lily, pearl, persimmon, cap, bokbok, yulmu and motherwort complex extracts have a superior antioxidant effect, anti-inflammatory effect, and wrinkles due to their synergy. It was confirmed that it shows an improvement effect and a whitening effect. Therefore, the cosmetic composition containing it as an active ingredient can be used as an antioxidant, anti-inflammatory, wrinkle improvement or whitening cosmetics.
본 발명의 화장료 조성물은 통상적으로 제조되는 어떠한 제형으로도 제조 될 수 있으며, 그 예로는 화장수, 크림, 에센스, 클렌징 폼, 클렌징 워터, 팩, 바디 로션, 바디 오일, 바디 젤, 샴푸, 린스, 헤어 컨디셔너, 헤어 젤, 파운데이션, 립스틱, 마스카라, 메이크업 베이스 등을 들 수 있다.The cosmetic composition of the present invention can be prepared in any conventional formulation, for example, lotion, cream, essence, cleansing foam, cleansing water, pack, body lotion, body oil, body gel, shampoo, rinse, hair Conditioners, hair gels, foundations, lipsticks, mascaras, and makeup bases.
[실시예][Example]
이하, 하기의 실시예와 시험예들을 통하여 본 발명을 상세하게 설명하지만, 본 발명이 이 예들에 의하여 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail through the following examples and test examples, but the present invention is not limited by these examples.
제조예 1: 모란꽃 추출물의 제조Preparation Example 1: Preparation of peony flower extract
모란꽃을 세척 건조한 후 중량대비 10배의 70% 에탄올을 이용하여 5일간 상온에서 추출 및 여과를 총 3회 반복 실시 후, 이를 모두 모아 감압 농축하여 농축액 약 12g을 얻었다.After washing and drying the peony flowers, extraction and filtration were repeated 3 times at room temperature for 5 days using 70
제조예 2: 설련화 추출물의 제조Preparation Example 2: Preparation of the extract of sseonhwa
설련화 꽃을 상기 제조예 1과 동일한 방법으로 추출하여 설련화 추출물을 제조하였다.To extract the flower of the snow lily was prepared in the same manner as in Preparation Example 1, to prepare a snow lily flower extract.
제조예 3: 진주 추출물의 제조Preparation Example 3: Preparation of pearl extract
진주 알갱이를 분쇄 후 200메쉬로 거른 파우더를 상기 제조예 1과 동일한 방법으로 추출하여 진주 추출물을 제조하였다.After pulverizing the pearl grains, the powder filtered with 200 mesh was extracted in the same manner as in Preparation Example 1 to prepare a pearl extract.
제조예 4: 감태 추출물의 제조Preparation Example 4: Preparation of persimmon extract
감태를 상기 제조예 1과 동일한 방법으로 추출하여 감태 추출물을 제조하였다.Persimmon extract was prepared in the same manner as in Preparation Example 1 to prepare persimmon extract.
제조예 5: 모자반 추출물의 제조Preparation Example 5: Preparation of capsicum extract
모자반을 상기 제조예 1과 동일한 방법으로 추출하여 모자반 추출물을 제조하였다.The extract was prepared in the same manner as in Preparation Example 1 to prepare the extract.
제조예 6: 선복화 추출물의 제조Preparation Example 6: Preparation of Sunbokhwa extract
선복화를 상기 제조예 1과 동일한 방법으로 추출하여 선복화 추출물을 제조하였다. The bokbok extract was extracted in the same manner as in Preparation Example 1 to prepare a bokbok extract.
제조예 7: 율무 추출물의 제조Preparation Example 7: Preparation of Yulmu extract
율무 열매를 상기 제조예 1과 동일한 방법으로 추출하여 율무 추출물을 제조하였다.Yulmu fruit was extracted in the same manner as in Preparation Example 1 to prepare Yulmu extract.
제조예 8 : 익모초 추출물의 제조Preparation Example 8: Preparation of motherwort extract
익모초 전초를 상기 제조예 1과 동일한 방법으로 추출하여 익모초 추출물을 제조하였다.Motherwort outpost was extracted in the same manner as in Preparation Example 1 to prepare motherwort extract.
실시예 1: 모란 복합추출물의 제조Example 1: Preparation of a complex peony extract
모란꽃 10g, 설련화 10g, 진주분말 20g, 감태 10g, 모자반 20g, 선복화 10g, 율무 10g 및 익모초 20g을 혼합하였다. 상기 혼합물을 중량대비 10배의 70% 에탄올을 이용하여 5일간 상온에서 추출 및 여과를 총 3회 반복 실시 후 이를 모두 모아 감압 농축하여 모란 복합추출물을 제조하였다.10 g of peony flowers, 10 g of snow lily, 20 g of pearl powder, 10 g of persimmon, 20 g of capwort, 10 g of sunbokhwa, 10 g of Yulmu and 20 g of motherwort. The mixture was extracted and filtered at room temperature for 5 days using 70
실시예 2 ~ 4: 모란 복합추출물의 제조Examples 2 to 4: Preparation of the complex extract of peonies
모란꽃, 설련화, 진주분말, 감태, 모자반, 선복화, 율무 및 익모초를 하기 표 1의 중량으로 변경하여 상기 실시예 1과 동일한 방법으로 모란 복합추출물을 제조하였다.Peony flowers, sseonhwa, pearl powder, persimmon, hat half, sunbokhwa, yulmu and motherwort were changed to the weight of Table 1 to prepare a peony composite extract in the same manner as in Example 1.
비교예 1: 모란 제외 복합추출물의 제조Comparative Example 1: Preparation of complex extract without peony
설련화 10g, 진주 20g, 감태 10g, 모자반 20g, 선복화 10g, 율무 10g 및 익모초 20g을 혼합하였다. 상기 혼합물을 중량대비 10배의 70% 에탄올을 이용하여 5일간 상온에서 추출 및 여과를 총 3회 반복 실시 후 이를 모두 모아 감압 농축하여 모란 복합 추출물을 제조하였다.10 g of ssoonhwa, 20 g of pearls, 10 g of persimmon, 20 g of caps, 10 g of sunbokhwa, 10 g of Yulmu and 20 g of motherwort were mixed. The mixture was extracted and filtered at room temperature for 5 days using 70
시험예 1: 항산화 활성 시험 Test Example 1: Antioxidant activity test
항산화활성을 평가하기 위하여 상기 제조예, 비교예 및 실시예의 추출물을 사용하여 DPPH 라디칼에 대한 프리라디칼 소거활성 시험(DPPH free radical scavenging effect assay)을 다음과 같은 방법으로 수행하였다.In order to evaluate the antioxidant activity, a free radical scavenging effect assay for DPPH radicals using the extracts of Preparation Examples, Comparative Examples and Examples was performed in the following manner.
DPPH는 시그마사(Sigma Co., Ltd, 미국)에서 구입하여 사용하였다. 먼저,400 ㎛ 농도의 표준 DPPH 용액을 만들었다. 그리고, 실시예 2 내지 4와 비교예를 각각 에탄올을 가하여 200 ㎍/㎖의 농도로 시료를 만들었다. 그 다음, 상기 시료와 표준 DPPH 용액을 같은 비율로 첨가하여 잘 교반한 후, 37 ℃에서 30 분간 반응시키고 520 ㎚에서 흡광도를 측정하였다. 하기식을 이용하여 자유라디칼 소거율(%)을 구하고, 50%의 free radical scavenging activity를 나타내는 EC50 값을 산출하여 그 결과를 하기 표 2에 나타내었다.DPPH was purchased and used by Sigma Co., Ltd. (USA). First, a standard DPPH solution of 400 μm concentration was made. Then, in Examples 2 to 4 and Comparative Examples, ethanol was added to prepare samples at a concentration of 200 µg/ml. Then, the sample and the standard DPPH solution were added at the same rate, stirred well, reacted at 37°C for 30 minutes, and absorbance was measured at 520 nm. The free radical scavenging rate (%) was calculated using the following equation, and the EC50 value representing 50% free radical scavenging activity was calculated and the results are shown in Table 2 below.
대조군으로 Ascorbic acid(100ppm)를 사용하였으며, 비교예 2로 모란 오일(모란씨를 압착하여 추출한 오일)을 사용하였다.Ascorbic acid (100ppm) was used as a control, and as a comparative example 2, peony oil (oil extracted by squeezing peony seeds) was used.
자유라디칼소거율(%)=100 - (시료의 반응흡광도/대조군의 반응흡광도) × 100Free radical scavenging rate (%)=100-(reaction absorbance of sample/reaction absorbance of control) × 100
상기 표 2에 나타나는 바와 같이 제조예 1의 모란꽃 추출물, 비교예 2의 모란오일, 실시예의 모란 복합추출물에서 항산화효과를 확인할 수 있었다. 제조예 2 내지 8의 추출물이나, 모란꽃을 제외한 비교예 1의 복합추출물에서는 항산화활성이 나타나지 않았지만, 모란꽃을 포함하는 본 발명 실시예의 복합추출물에서는 우수한 항산화활성이 나타나는 것을 확인할 수 있었다. 실시예 1의 복합추출물에서 가장 우수한 항산화활성이 나타났다.As shown in Table 2, the anti-oxidant effect was confirmed in the peony flower extract of Preparation Example 1, the peony oil of Comparative Example 2, and the peony complex extract of Example. Antioxidant activity was not observed in the extracts of Preparation Examples 2 to 8 or the composite extract of Comparative Example 1 except for the peony flower, but it was confirmed that excellent antioxidant activity was exhibited in the complex extract of the example of the present invention containing the peony flower. The best antioxidant activity was found in the complex extract of Example 1.
시험예 2: 세포증식확인 Test Example 2: Confirmation of cell proliferation
상기 제조예 1, 비교예 1 및 실시예 1의 추출물들에 대해 Cell viability assay를 다음과 같은 방법으로 수행하였다.Cell viability assay was performed on the extracts of Preparation Example 1, Comparative Example 1 and Example 1 in the following manner.
먼저 사람의 섬유아세포(human fibroblast cell)를 96웰 플레이트(96 well plate, Corning사)에 접종하여 배양한 다음 비교예 1, 실시예 1 및 제조예 1을 각 농도별로 2일간 적용하고, MTT 시험 방법을 수행하여 세포증식을 평가하였다. 대조군으로는 무혈청 배지를 사용하였다. First, human fibroblast cells were inoculated in a 96-well plate (96 well plate, Corning) and cultured, and then Comparative Example 1, Example 1 and Preparation Example 1 were applied for each concentration for 2 days, and the MTT test was performed. The method was performed to evaluate cell proliferation. Serum-free medium was used as a control.
세포생존율은 아래의 식에 따라 계산하였으며 그 결과는 도 1에 나타내었다.Cell viability was calculated according to the following formula and the results are shown in FIG. 1.
세포생존율(%)=(각 시료의 흡광도)/(대조군 흡광도) × 100Cell viability (%) = (absorbance of each sample) / (control absorbance) × 100
도 1에서 확인되는 바와 같이, 실시예 1의 모란 복합추출물에서 농도별 세포증식(Cell proliferation)이 나타나는 것을 알 수 있다.As can be seen in Figure 1, it can be seen that the cell proliferation (Cell proliferation) by concentration in the peony complex extract of Example 1.
시험예 3: 항염 활성 확인(NO assay)Test Example 3: anti-inflammatory activity confirmation (NO assay)
상기 제조예 1, 비교예 1 및 실시예 1의 추출물들에 대해 항염 활성 평가를 다음과 같은 방법으로 수행하였다.The anti-inflammatory activity was evaluated for the extracts of Preparation Example 1, Comparative Example 1 and Example 1 in the following manner.
먼저, 대식세포주인 RAW 246.7 세포를 10% Fetal bovine serum(FBS), 1% Penicillin/streptomycin(P/S)이 함유된 Dulveccos's modified eagles medium(DMEM) 배지를 사용하여 37℃, 5% CO2 조건의 항온 배양기에서 배양을 하였다. 세포를 48well culture plate에 well 당 6 × 104 세포를 처리하고 24시간 배양하였다. 배양 후 농도별(5, 100, 200μg/mL)로 희석한 제조예 1, 비교예 1 및 실시예 1을 처리하고 1시간 후에 Lipo poly saccharide(LPS)를 1μg/mL의 농도로 각 well에 처리한 후 22시간 추가 배양하였다. 배양이 완료되면 세포배양액 100μL와 Griess 시약[1%(w/v) sulfanilamide, 0.1% N-1-napthylethylene diamine in 2.5% (w/v) phosphoric acid] 100μL을 혼합하여 96 well plate에서 10분 동안 반응시킨 후 540nm에서 흡광도를 측정하였다. 아질산염 나트륨(Sodium nitrate)를 이용해 표준곡선을 구하고 이를 이용해 생성된 아질산염 값을 산출하여, 그 결과를 도 2에 나타내었다. First, the macrophage cell line RAW 246.7 cells using 10% Fetal bovine serum (FBS), 1% Penicillin/streptomycin (P/S) containing Dulveccos's modified eagles medium (DMEM) medium at 37 ℃, 5% CO 2 conditions It was cultured in a constant temperature incubator. Cells were treated with 6×10 4 cells per well in a 48-well culture plate and cultured for 24 hours. After incubation, treatment was performed with Preparation Example 1, Comparative Example 1, and Example 1 diluted to concentrations (5, 100, 200 μg/mL), and after 1 hour, Lipo poly saccharide (LPS) was treated in each well at a concentration of 1 μg/mL. After that, the cells were further cultured for 22 hours. When culture is complete, mix 100 μL of cell culture solution and 100 μL of Griess reagent [1% (w/v) sulfanilamide, 0.1% N-1-napthylethylene diamine in 2.5% (w/v) phosphoric acid] for 10 minutes in a 96 well plate. After the reaction, absorbance was measured at 540 nm. A standard curve was obtained using sodium nitrate, and the resulting nitrite value was calculated, and the results are shown in FIG. 2.
도 2에서 확인되는 바와 같이 제조예 1의 모란추출물, 비교예 1의 모란 제외 복합추출물에서도 항염 활성을 확인할 수 있지만, 본 발명 실시예 1의 모란 복합추출물에서 더 우수한 항염 활성을 나타내었다. 실시예 1의 모란 복합추출물에서 농도 의존적으로 유의하게 감소됨을 확인할 수 있다.As can be seen in Figure 2, although the anti-inflammatory activity can be confirmed in the peony extract of Preparation Example 1 and the peony extract of Comparative Example 1, it showed better anti-inflammatory activity in the peony composite extract of Example 1 of the present invention. It can be seen that the peony complex extract of Example 1 is significantly decreased in a concentration-dependent manner.
시험예 4: MMP-1 AssayTest Example 4: MMP-1 Assay
상기 제조예 1, 비교예 1 및 실시예 1의 추출물들에 대해 주름개선 활성을 다음과 같은 방법으로 평가하였다.Wrinkle improvement activity of the extracts of Preparation Example 1, Comparative Example 1 and Example 1 was evaluated in the following manner.
인간 유래의 섬유아세포(human fibroblast 세포)를 5 × 104cells/well 농도로 24-웰 플레이트(well plate)에 접종한 후, 24시간 동안 37℃, 5% CO2 조건의 인큐베이터에서 안정화시켰다. 그 후, 세포를 PBS로 2번 헹구어 제거하고 0.2% FBS가 첨가된 배양배지로 교환하였으며, 제조예 1, 비교예 1 및 실시예 1의 추출물을 각 세포에 48시간 동안 처리하였다. 48시간 후, 상층액만을 수득하였으며 human total MMP-1 ELISA kit (human total MMP-1 Cat.no. DY901, R&D systems)'를 이용해 분광광도계로 450 nm의 파장에서 흡광도를 측정하여 그 결과를 도 3에 나타내었다.Human-derived fibroblasts (human fibroblast cells) were inoculated into 24-well plates at a concentration of 5×10 4 cells/well and stabilized in an incubator at 37° C. and 5% CO 2 conditions for 24 hours. Thereafter, the cells were rinsed twice with PBS, removed, and exchanged with a culture medium to which 0.2% FBS was added, and the extracts of Preparation Example 1, Comparative Example 1 and Example 1 were treated for 48 hours for each cell. After 48 hours, only the supernatant was obtained and the absorbance was measured at a wavelength of 450 nm with a spectrophotometer using a human total MMP-1 ELISA kit (human total MMP-1 Cat.no.DY901, R&D systems). It is shown in 3.
도 3에서 확인되는 바와 같이, 제조예 1의 모란 추출물에서도 농도 의존적으로 MMP-1 발현이 감소됨을 알 수 있지만, 실시예 1의 모란 복합추출물에서 그 발현이 현저히 감소함을 알 수 있다. 이로써 실시예 1의 모란 복합추출물의 우수한 주름개선활성을 확인할 수 있다. As can be seen in Figure 3, although it can be seen that the concentration-dependent MMP-1 expression is also reduced in the peony extract of Preparation Example 1, it can be seen that the expression is significantly reduced in the peony complex extract of Example 1. As a result, excellent wrinkle improvement activity of the peony composite extract of Example 1 can be confirmed.
시험예 5: Procollagen AssayTest Example 5: Procollagen Assay
상기 제조예 1, 비교예 1 및 실시예 1의 추출물들에 대해 주름개선 활성을 다음과 같은 방법으로 평가하였다.Wrinkle improvement activity of the extracts of Preparation Example 1, Comparative Example 1 and Example 1 was evaluated in the following manner.
상기 제조예 1, 비교예 1 및 실시예 1의 추출물을 각각 인간 유래의 섬유아세포(human fibroblast 세포)의 배양배지에 첨가하여 1 일간 배양한 후, 배양액을 취하여 PICP EIA Kit로 각 농도에서 콜라겐 합성 정도를 분광광도계를 이용하여 450 ㎚에서 측정하였다. 이때, 효과의 비교를 위하여 아무것도 첨가하지 않은 섬유아세포의 배양배지(대조군)를 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였고 그 결과를 도 4에 나타내었다.The extracts of Preparation Example 1, Comparative Example 1 and Example 1 were added to the culture medium of human-derived fibroblasts, and cultured for 1 day. Then, the culture solution was taken and collagen was synthesized at each concentration with PICP EIA Kit. The degree was measured at 450 nm using a spectrophotometer. At this time, the collagen synthesis degree was measured in the same way for the sample to which the culture medium (control) of fibroblasts to which nothing was added was added for comparison of effects, and the results are shown in FIG. 4.
도 4에서 확인되는 바와 같이, 다른 시료에서와 달리 실시예 1의 모란 복합추출물의 경우 1%의 농도에서 Procollagen 발현이 크게 증가됨을 알 수 있다.As can be seen in Figure 4, unlike other samples, it can be seen that the peony complex extract of Example 1 significantly increases Procollagen expression at a concentration of 1%.
시험예 6: 미백활성 확인Test Example 6: Whitening activity confirmation
상기 제조예 1, 비교예 1 및 실시예 1의 추출물들에 대해 미백 활성을 다음과 같은 방법으로 평가하였다.The whitening activity of the extracts of Preparation Example 1, Comparative Example 1 and Example 1 was evaluated in the following manner.
먼저, 상기 제조예 1, 비교예 1 및 실시예 1의 추출물에 하이드로퀴논 수용액과 함께 각각 악성 멜라닌 종양 세포(B-16 mouse melanoma cell)의 배지에 첨가하여 3일간 배양한 후, 트립신을 처리하여 세포들을 배양 용기로부터 떼어내 원심분리한 후 멜라닌을 추출하였다. 여기에 수산화나트륨 용액(1N농도) 1ml을 가하여 10분간 끓여 멜라닌을 녹이고 분광광도계를 이용하여 400nm에서의 흡광도를 측정하여 생성된 멜라닌의 양을 단위 세포수당 흡광도로 나타내는 방법으로 수행하였다. 상기 실험을 3회 이상 반복하여 측정하였으며, 대조군에 대한 상대적인 멜라닌 생성량을 저해율(%)로 계산하였고, 그 결과를 도 5에 나타내었다.First, the extracts of Preparation Example 1, Comparative Example 1 and Example 1 were added to the medium of malignant melanin tumor cells (B-16 mouse melanoma cell) together with aqueous hydroquinone solution, and cultured for 3 days, followed by treatment with trypsin. Cells were removed from the culture vessel and centrifuged to extract melanin. To this, 1 ml of sodium hydroxide solution (1 N concentration) was added, boiled for 10 minutes to dissolve melanin, and the absorbance at 400 nm was measured using a spectrophotometer to measure the amount of melanin produced as absorbance per unit cell. The experiment was repeated three or more times, and the amount of melanin produced relative to the control was calculated as the inhibition rate (%), and the results are shown in FIG. 5.
도 5에서 확인되는 바와 같이, 제조예 1의 모란 추출물은 melanogenesis에 영향을 주지 못하고, 비교예 1의 모란 제외 복합추출물에서는 오히려 농도 의존적으로 melanogenesis가 증가하여 색이 진하게 나타남을 알 수 있다. 그런데 다른 시료에서와 달리 실시예 1의 모란 복합추출물의 경우 농도 의존적으로 melanogenesis가 감소하였다.As can be seen in Figure 5, it can be seen that the peony extract of Preparation Example 1 does not affect melanogenesis, and in the complex extract except for the peony of Comparative Example 1, the melanogenesis increases in a concentration-dependent manner, and the color appears dark. However, unlike other samples, in the case of the peony complex extract of Example 1, melanogenesis was decreased in a concentration-dependent manner.
제형 실시예 1: 모란 복합추출물을 함유하는 세럼의 제조 Formulation Example 1: Preparation of Serum Containing Peony Complex Extract
모란 복합추출물(실시예 1)을 함유한 세럼을 하기의 표 3의 조성 및 함량으로 통상의 방법에 따라 제조하였다.Serum containing the peony complex extract (Example 1) was prepared according to the conventional method with the composition and content of Table 3 below.
제형 실시예 2: 복합추출물을 함유하는 크림의 제조Formulation Example 2: Preparation of a cream containing a complex extract
모란 복합추출물(실시예 1)을 함유하는 크림을 하기의 표 4의 조성 및 함량으로 통상의 방법에 따라 제조하였다.The cream containing the peony complex extract (Example 1) was prepared according to the conventional method with the composition and content of Table 4 below.
시험예 7: 제형안정도 확인Test Example 7: Confirmation of formulation stability
상기 제형 실시예 1, 2에서 제조한 제형에 대하여 실온(25℃), 냉장(4℃) 및 항온(50℃)으로 일정하게 유지되는 실내, 냉장고 및 인큐베이터에서 불투명 초자 용기에 담아 12주 동안 보관 및 관찰(변색, 변취 및 분리)하며, 안정성을 확인 하였다. 결과는 표 5에 나타내었다.For the formulations prepared in Examples 1 and 2 of the above formulations, they are stored in an opaque vial container in a room, refrigerator and incubator kept constant at room temperature (25°C), refrigeration (4°C) and constant temperature (50°C) and stored for 12 weeks. And observation (discoloration, odor and separation), and stability was confirmed. Table 5 shows the results.
< 제형 안정 등급 ><Formulation stability grade>
0: 변화 없음 1: 미세한 변화 2: 변화 3: 극심한 변화0: No change 1: Minor change 2: Change 3: Severe change
상기 표에서 나타낸 바와 같이 제형 실시예 1, 2 제형 모두 25℃, 4℃ 및 50℃ 온도 조건하에서 변색, 변취 및 분리 현상이 나타나지 않고 안정함이 확인되었다.As shown in the above table, it was confirmed that both the formulation examples 1 and 2 formulations were stable without discoloration, odor and separation under 25°C, 4°C and 50°C temperature conditions.
Claims (7)
The cosmetic composition according to claim 1, wherein the cosmetic composition is used for whitening.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180115133A KR102119316B1 (en) | 2018-09-27 | 2018-09-27 | Cosmetic composition containing Paeonia suffruticosa complex extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180115133A KR102119316B1 (en) | 2018-09-27 | 2018-09-27 | Cosmetic composition containing Paeonia suffruticosa complex extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200035700A KR20200035700A (en) | 2020-04-06 |
KR102119316B1 true KR102119316B1 (en) | 2020-06-04 |
Family
ID=70282013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180115133A KR102119316B1 (en) | 2018-09-27 | 2018-09-27 | Cosmetic composition containing Paeonia suffruticosa complex extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102119316B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220083616A (en) | 2020-12-10 | 2022-06-20 | 주식회사 소윌로 | Cosmetic composition for relieving skin irritation with the extract of Paeonia suffruticosa root |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100970544B1 (en) * | 2002-11-07 | 2010-07-16 | 코세 코퍼레이션 | Skin external composition and its use method |
KR101081059B1 (en) * | 2009-06-30 | 2011-11-07 | 한국콜마 주식회사 | Flowers Extract Having Anti-oxidation And Whitening Effects And Extraction Method Thereof And Cosmetics Comprising Flowers Extract |
KR20170076966A (en) * | 2015-12-24 | 2017-07-05 | 주식회사 제닉 | Composition for anti-wrinkle and method for preparing the same |
-
2018
- 2018-09-27 KR KR1020180115133A patent/KR102119316B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220083616A (en) | 2020-12-10 | 2022-06-20 | 주식회사 소윌로 | Cosmetic composition for relieving skin irritation with the extract of Paeonia suffruticosa root |
Also Published As
Publication number | Publication date |
---|---|
KR20200035700A (en) | 2020-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102212305B1 (en) | A cosmetic composition comprising plant extract as active ingredient, and a preparation method of thereof | |
KR101800213B1 (en) | Skin Whitening Cosmetic Composition Containing Extracts of Acer barbinerve Max., Acer barbinervis var. glabrescens or Acer tschonoskii var. rubripes | |
KR101309172B1 (en) | Composition for preventing from inflammation | |
KR100753186B1 (en) | Skin anti-aging cosmetic composition containing herbal extract mixture | |
KR102119316B1 (en) | Cosmetic composition containing Paeonia suffruticosa complex extract | |
KR101420211B1 (en) | Skin Composition for External Application Using Bud and Sprout Extract | |
KR101982510B1 (en) | Cosmetic composition containing algae extract, silver vine extract and manchurian violet extract | |
KR100977673B1 (en) | Cosmetic composition for promoting blood circulation and improving skin color containing a complex of plant extracts (Chillbaek Jingo extract) | |
KR102100345B1 (en) | A cosmetic composition comprising ligustrum lucidum extract | |
KR20110032715A (en) | Anti-aging cosmetic composition and preparation method thereof | |
KR101171761B1 (en) | Cosmetic composition for combatting aging the skin | |
KR102208482B1 (en) | Cosmetic composition for improving skin troubles | |
KR102149223B1 (en) | Cosmetic composition for skin whitening containing the fermented complex natural extracts | |
KR20170107943A (en) | Skin Whitening Cosmetic Composition Containing Extracts of Wikstroemia trichotoma | |
KR102171472B1 (en) | a Composition for improving Hair growth containing a leaf extract of Dendropanax Morbifera and a extract of Hallabong rind | |
KR100512690B1 (en) | Cosmetic composition containing bletilla striata and leontopodium alpinum extract | |
KR20090077619A (en) | Cosmetic composition containing herbal extracts effective for wrinkle improvement | |
KR20200088027A (en) | Compositions having improved blood flow and cell proliferation activity | |
KR101981959B1 (en) | Cosmetic Compositions for Anti-oxidation and Moisturizing Comprising Extracts of Plants | |
KR101966188B1 (en) | Cosmetic Compositions for Anti-oxidation and Anti-wrinkling Comprising Extracts of Plants | |
KR102467403B1 (en) | Composition for preventing hair loss and promoting hair growth and method for manufacturing thereof | |
KR102119823B1 (en) | A cosmetic composition comprising morus bombycis extract | |
KR101820881B1 (en) | Skin Whitening Cosmetic Composition Containing Extracts of Daphne kamtschatica | |
KR101596576B1 (en) | Cosmetic composition and a method of manufacturing | |
KR100529776B1 (en) | Compositions of whitening cosmetics containing special herbal extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20180927 |
|
PA0201 | Request for examination | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191114 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200515 |
|
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200529 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20200529 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20240309 |